Weekly affective symptom severity and polarity were compared in 135 bipolar I (BP I) and 71 bipolar II (BP II) patients during up to 20 yr of prospective symptomatic follow-up. The course of BP I and BP II was chronic; patients were symptomatic approximately half of all follow-up weeks (BP I 46.6 % and BP II 55.8 % of weeks). Most bipolar disorder research has concentrated on episodes of MDD and mania and yet minor and subsyndromal symptoms are three times more common during the long-term course. Weeks with depressive symptoms predominated over manic/hypomanic symptoms in both disorders (3:1) in BP I and BP II at 37:1 in a largely depressive course (depressive symptoms=59.1 % of weeks vs. hypomanic=1.9 % of weeks). BP I patients had more weeks of cycling/mixed polarity, hypomanic and subsyndromal hypomanic symptoms. Weekly symptom severity and polarity fluctuated frequently within the same bipolar patient, in which the longitudinal symptomatic expression of BP I and BP II is dimensional in nature involving all levels of affective symptom severity of mania and depression. Although BP I is more severe, BP II with its intensely chronic depressive features is not simply the ' lesser' of the bipolar disorders; it is also a serious illness, more so than previously thought (for instance, as described in DSM-IV and ICP-10). It is likely that this conventional view is the reason why BP II patients were prescribed pharmacological treatments significantly less often when acutely symptomatic and during intervals between episodes. Taken together with previous research by us on the long-term structure of unipolar depression, we submit that the thrust of our work during the past decade supports ' classic' notions of a broader affective disorder spectrum, bringing bipolarity and recurrent unipolarity closer together. However the genetic variation underlying such a putative spectrum remains to be clarified.
Introduction
Previous studies of bipolar disorders have focused almost exclusively on full syndromal episodes of major depression (MDE) and mania (e.g. Angst, 1986; Cassano et al., 1989; Coryell et al., 1984; Koukopoulos et al., 1980; Winokur et al., 1994) . However, our work has demonstrated the value of detailed analysis of the long-term weekly symptomatic status, in that the modal longitudinal symptomatic expression of the bipolar I (BP I) and bipolar II (BP II) disorders primarily involves symptoms at the minor and sub-syndromal level of severity rather than at the syndromal level of MDE or mania (Judd et al., 2002 (Judd et al., , 2003a . Looking at each disorder separately, it also appears that the longitudinal symptomatic expression of both BP I and BP II disorders is dimensional in character, featuring the full range of affective symptom severity and polarity.
Also, in a prior report, to help clarify further the relationship between these two disorders (Judd et al., 2003b) , the frequency, duration and polarity of affective episodes of BP I and BP II disorders during the longterm course of these illnesses were compared. We now extend the findings of these earlier reports by comparing similarities and differences in the longitudinal weekly symptomatic status of BP I and BP II. This was also an opportunity to test the suggestion of others that BP I is more severe while BP II is more chronic (Ayuso-Gutierrez and Ramos-Brieva, 1982; Vieta et al., 1997) . In the present paper, the weekly affective symptom severity and polarity was compared in two large cohorts of BP I and BP II patients who are being followed for up to 20 yr as part of the NIMH Collaborative Depression Study (CDS), which is an ongoing prospective, longitudinal investigation of the characteristics and course of affective disorders.
Subjects and methods

Subjects
Since the major purpose of this investigation was to contrast the long-term symptomatic status of BP I and BP II, the two analysis samples were constructed to be as diagnostically comparable as possible to ensure valid comparisons. Unlike prior studies we have reported (Judd et al., 2002 (Judd et al., , 2003a , the cohorts of BP I and BP II patients analysed herein were defined as follows : (1) Each patient met criteria for definite Research Diagnostic Criteria (RDC) bipolar disorder by virtue of having either a lifetime manic (BP I) or hypomanic episode of at least 1 wk duration, as well as a depressive episode of at least 2 wk duration (minor, major) or dysthymia. (2) Each patient had to meet bipolar diagnostic criteria at the time of intake into the study and at their last evaluation. The eliminated patients entering the study with unipolar depressive disorder who later converted to a bipolar diagnosis and BP II patients who converted to BP I. As a result, the analysis samples consisted of 135 BP I and 71 BP II patients entering the CDS from 1978 up to 1981 (Katz and Klerman, 1979; at one of five academic centres (Massachusetts General Hospital and Harvard University, New York Psychiatric Institute and Columbia University, University of Iowa, Rush Presbyterian -St Luke's Medical Center in Chicago, or Washington University in St Louis), during an index affective episode. Bipolar diagnosis was based on the Schedule of Affective Disorders and Schizophrenia (SADS) (Spitzer and Endicott, 1979) using RDC (Spitzer et al., 1977) . Further, patients were eliminated from the analysis samples if they had any evidence of schizophrenia or schizoaffective disorder, at intake or during follow-up. Subjects were Caucasian (genetic hypotheses were being tested), spoke English, had an IQ score of at least 70, and had no evidence of organic mental disorder or terminal medical illness at intake. All patients gave informed consent at each academic site. Demographic and clinical characteristics of the BP I and BP II study samples are summarized in Table 1 .
Assessment of follow-up course
Trained raters interviewed patients every 6 months for the first 5 yr of follow-up, and continue to interview them annually, using variations of the Longitudinal Interval Follow-up Evaluation (LIFE ; Keller et al., 1987) . Patient interviews are the primary information source for LIFE data, with chronological memory prompts used to obtain information on changes in weekly symptom severity for all mood and other mental disorders. Interview information, supplemented by available medical records is integrated into weekly symptom severity ratings using LIFE Psychiatric Status Rating (PSR) scales, which are anchored to diagnostic thresholds for RDC mental disorders. CDS raters routinely undergo rigorous training (Keller et al., 1987) , resulting in high intra-class correlation coefficients (ICCs) for rating changes in symptoms (ICC=0.92), recovery from episodes (ICC=0.95) and subsequent reappearance of symptoms (ICC=0.88).
In addition, interviewers assign a 5-point rating of the accuracy of weekly PSR information based on their overall impression of the subject's recall, the internal consistency of information provided, and evidence of denial or distortion of illness status. If a subject is severely manic or depressed at scheduled time of follow-up, the interview is rescheduled at a later time. Of the 3550 LIFE forms available for the bipolar samples analysed in this paper, 25.0 % were rated ' excellent', 53.2 % 'good', 19.5 % 'fair ', 2.0 % ' poor', and 0.3 % ' very poor ' in terms of accuracy of information of weekly psychiatric status. A total of 147 CDS patients met diagnostic criteria for BP I, and 77 met criteria for BP II disorder as of intake. Since the present analyses focused on weekly symptom status during long-term follow-up, we eliminated from the analyses 12 BP I patients (8.2 %) and 6 BP II patients (7.8 %) who had less than 2 yr of weekly PSR data rated 'excellent ', ' good', or 'fair ' in terms of accuracy, because they died or dropped out of the CDS study before 2 yr elapsed. This left 135 BP I and 71 BP II patients with between 2 and 20 yr of weekly prospective follow-up data rated 'fair ' or better in terms of accuracy: BP I mean=12.8 yr (S.D.=5.7 yr, median=15.5 yr) of follow-up, and BP II mean=13.2 yr (S.D.=6.2 yr, median=16.0 yr) of follow-up (t=0.43, d.f.=204, p=0.665).
The CDS is a naturalistic follow-up study; it was not designed as a controlled treatment investigation. However, the nature and dose regimen of all somatic treatments (i.e. antidepressants, mood stabilizers, antipsychotics, ECT) was recorded regularly on a weekly basis on the LIFE forms.
Classification of weekly symptom severity levels
Methods previously reported in detail (Judd et al., 1998 (Judd et al., , 2002 were used to assign each weekly affective symptom severity level. Outlined in Table 2 are the four categories of affective symptom severity levels based on the 6-point PSR scale and for major depression and mania, plus the 3-point PSR scale for rating minor depression/dysthymia, hypomania, DSM-IV atypical depression, DSM-III adjustment disorder with depressed mood and RDC cyclothymic personality. Affective symptom severity levels are anchored to the diagnostic thresholds for all affective conditions including MDE, minor depressive/ dysthymic disorder, and hypomania, but weekly levels were assigned regardless of whether the patient was in an RDC defined episode. Affective symptoms below the thresholds of these RDC disorders were classified as subsyndromal depression or subsyndromal hypomania. Weeks with no affective symptoms were classified as asymptomatic. Weeks with affective symptoms were then separated in to weeks of pure depression (no mania/hypomania), pure mania or hypomania (no depression), or a combination of manic/hypomanic and depressive symptoms (cycling/ mixed affective symptoms).
Statistical analyses
Statistical comparisons on background characteristics were made between the two bipolar groups by means of x 2 or t tests. Follow-up weeks spent at the different symptom status categories were computed for each patient as percentages of the total number of follow-up weeks with PSR ratings of ' fair' or better accuracy; these were then compared for BP I vs. BP II by t tests. For subsets of patients who experienced one or more weeks in a given symptom status category, the percentage of weeks with some prescribed somatic treatment was computed ; these were compared by Wilcoxon Rank Sum tests. A two-tailed a-level of p=0.05 was used to define statistically significant group comparisons.
Results
Demographic characteristics and clinical history
As seen in Table 1 , BP I and BP II patients did not differ in mean age, sex, marital status, or level of education. There were no significant differences in clinical history at intake, although BP II patients had a nonsignificant trend to have had more prior affective episodes (mean=36.6, S.D.=51.2) than BP I patients (mean=24.2, S.D.=45.5). Both cohorts experienced their first affective episodes at approximately the same age and began their course of illness primarily with depressive episodes. As reported elsewhere, for these samples (Judd et al., 2003b) , BP I patients were more severely ill at intake as indicated by their significantly higher inpatient status (x 2 =38.4, d.f.=1, p=0.001), lower Global Assessment scores (t=3.06, d.f.=204, p=0.002), and three times higher prevalence of psychotic features in the intake episode (x 2 =25.4, d.f.=1, p=0.001). In addition, the median duration of the intake episode after admission to the CDS (from survival analysis) was about twice as long for BP II as for BP I patients (Wilcoxon x 2 =11.20, p=0.0008).
Percentage of follow-up weeks spent at three symptom severity levels and at asymptomatic status During their follow-up course ( Percentage of follow-up spent in affective symptom severity categories divided by polarity Table 4 shows the percentage of weeks when the symptom severity levels are divided by polarity. BP II patients were found to spend significantly more follow-up weeks with depressive symptoms (major, minor and subsyndromal depressive) compared to the BP I (t=4.45, d.f.=115.8, p=0.0001). In fact, the BP II patients spent 37 times more weeks with depressive symptoms (51.9 % of weeks) than hypomanic symptoms (1.4 % of weeks). However, BP I patients also had three times as many weeks with depressive symptoms (30.6 % of weeks) than with manic/hypomanic symptoms (9.8 % of weeks).
Within the depressive symptom spectrum, BP II patients spent significantly more of follow-up weeks 
Changes in symptom status and polarity during follow-up
Changes in symptom status were defined as any week-to-week change in symptom severity level and/ or polarity. As shown in Table 5 , BP I patients had somewhat more annual changes in weekly symptom status (mean=5.9, S.D.=7.7) compared to BP II (mean=3.8, S.D.=4.9). Also, BP I patients experienced substantially more annual shifts in affective symptom polarity. Neither of these comparisons were subjected to statistical analyses, because it is possible that any differences might have been due to definitional issues whereby BP I, compared to BP II patients, can experience a greater number of possible changes in symptom status due to the absence of mania in BP II.
Somatic treatment during weeks at each symptom status category
As shown in 
Commentary
This is the first detailed comparison of the weekly symptomatic status of BP I and BP II patients during a mean of approx. 13 yr of follow-up. Both disorders were surprisingly chronic in that patients were symptomatic from their disorders about half the time -an average of 46.6 % of follow-up weeks for BP I and 55.8 % for BP II. It is of interest that weekly symptom severity for both BP I and BP II primarily involved symptoms of moderate severity (minor depression or hypomania) or subsyndromal affective symptoms which, taken together, were three times more common than symptoms at the syndromal level of major depression or mania. Virtually all previous research has been focused on syndromal episodes, and yet most of the long-term symptomatic course of these two disorders is expressed symptomatically below the full syndromal threshold. The longitudinal weekly course of both cohorts primarily involves depressive -not manic and hypomanic a Any week-to-week change in level of depressive and/or manic/hypomanic symptoms, or change from/to the asymptomatic status counts as +1. Weeks with symptoms of both depression and mania/hypomania add +1 to the count. b Change in polarity is defined as a change from some level of depression to some level of mania/hypomania or vice versa, with or without intervening weeks at the asymptomatic status. Weeks with symptoms of both depression and mania/hypomania add +1 to the count.
symptoms. BP I patients experienced weeks of depressive symptoms about three times more often than manic or hypomanic symptoms. However, it is striking that BP II patients were largely symptomatic with depression, in which weeks with depressive symptoms (51.9 % of follow-up weeks) were 37 times more common than weeks with hypomanic or subsyndromal hypomanic symptoms (1.4 % of follow-up weeks). In fact, BP II patients spent a significantly higher percentage of follow-up at the minor depressive (25.1 vs. 13.1 % of weeks) and subsyndromal depressive levels (14.2 vs. 8.8 % of weeks) than BP I patients. On the other hand, BP I patients had a seven times higher percentage of weeks with manic/hypomanic symptoms than BP II patients (9.8 vs. 1.4 % of follow-up), as well as significantly more weeks with symptoms of cycling/mixed polarity (6.0 vs. 2.5 % of follow-up). The course of BP I fluctuated more than in BP II patients as evidenced by a higher number of annual shifts in symptom polarity and status during followup. The more frequent symptom status shifts for BP I patients might in part be accounted for by the fact that BP I patients can move into and out of more symptom status levels than the BP II patients who do not experience mania.
Despite the differences described above, BP I and BP II do share a number of similar characteristics. Both disorders feature primarily depressive symptoms during their course of illness. Even BP I, traditionally defined by its dramatic, explosive manic episodes, experienced depressive symptoms three times more commonly during the course of illness than manic or hypomanic symptoms. The long-term symptomatic expression of both disorders is characterized by more moderate and subsyndromal affective symptoms. Also, both disorders are highly chronic in nature, with patients being symptomatically ill for approximately half of their long-term course of illness.
In prior analyses we have developed a new measure of chronicity, the total percentage of follow-up weeks with affective symptoms at any level which has proven to be a useful and sensitive measure of chronicity. In a previous report of the formal episode course of BP I and BP II patients (Judd et al., 2003b) , we found that BP I patients were in a formal RDC affective episode an average of 24 % of weeks during follow-up, compared to 32 % of weeks for BP II. However, during an episode, patients spent the majority of their weeks below full syndromal threshold, and periods between formal episodes included substantial numbers of weeks with residual subsyndromal affective symptoms. Thus, analysis of the weekly symptom status during all of follow-up has provided a complementary and more detailed picture of chronicity of bipolar patients' during the long-term course of their illness.
Although it was not the purpose of this paper to investigate possible factors accounting for the greater chronicity of BP II, based on information in patients' psychiatric records, we did find an intriguing result relative to treatment. Overall, BP II patients were much less likely than BP I patients to have been prescribed some (i.e. any level or type) somatic treatment (antidepressants, mood stabilizers, antipsychotics, ECT, etc.) during weeks in most affective symptom severity categories. For example, BP II patients were prescribed some somatic treatment during only 60.4 % of weeks when they were at the MDE threshold, whereas BP I patients had some treatment prescribed during 76.0 % of weeks when experiencing MDE level symptoms. During weeks BP II patients spent with minor depressive/dysthymic symptoms, they were treated 56.9 % of the time -far less than the 77.2 % of weeks BP I patients were treated while at the same minor depressive symptom severity level. Interestingly, during weeks when patients were symptomfree between episodes, BP II had some somatic treatment prescribed 43.5 % of the time, and BP I had treatment prescribed during 73.7 % of the time. While these findings do not address the dosage, drug type, or adequacy of psychotropic medication or other somatic treatments for bipolar disorders, it makes a compelling case for the conclusion that clinicians may underrecognize or minimize the chronic and highly depressive nature of BP II and, consequently, under-prescribe for this disorder in both acute and maintenance treatment. It should be noted that the CDS is naturalistic (not designed as a treatment study), and these observations are based on treatment data that was recorded but not controlled.
Among others, our data confirm observations by Vieta et al. (1997) in a smaller clinical sample showing that BP II disorder tends to be more chronic, and BP I more severe cross-sectionally. Although BP I is uniquely characterized by its more severe manic episodes, whereas BP II is not, nonetheless both cohorts had virtually identical percentages of follow-up weeks at the syndromal episode threshold (i.e. BP I=12.3 % of weeks and BP II=12.6 % of weeks). However, the intensely chronic and the disabling nature of depressive symptoms which make up over 50 % of the total course of BP II, highlights the fact that BP II is a serious chronic illness, and not necessarily the 'lesser ' of bipolar disorders (Judd et al., 2003a,b) . The present analysis of weekly symptom status goes beyond previous reports of the considerable chronicity of BP II (Akiskal, 1981 ; Benazzi, 2001; Coryell et al., 1989; Judd et al., 2003a) by emphasizing course similarities and differences with BP I and the need for enhanced treatment of BP II patients.
Although inter-rater agreement was high, there may be some degree of error in assigning weekly symptom status in retrospective interviews. There also may have been some tendency for CDS raters to focus on full syndromal symptoms of MDE and mania, and under-estimate symptoms at the minor depressive or hypomanic level. Also, the percentage of subsyndromal symptom weeks may be underestimated and the asymptomatic weeks overestimated, since PSR coding rules prohibit the recording of subsyndromal symptomatic symptoms following asymptomatic recovery until symptoms again reach syndromal levels. This could also result in an under-estimation of the number of polarity shifts into and out of the two subsyndromal symptom categories. Finally, it is uncertain how the differences in percentage of weeks at the various symptom severity levels were influenced by the unevenly distributed somatic therapies in BP I vs. BP II.
Combining data from the present analyses with previous findings in MDD (Judd et al., 1998; Kendler and Gardner, 1998) , in BP I (Judd et al., 2002) and BP II (Judd et al., 2003a) cohorts suggest there may be an overall affective disorder spectrum which includes all three of these disorders. Commonalties between these disorders supporting this proposition include first, a high degree of long-term weekly symptomatic chronicity with MDD patients being symptomatic approx. 60 % of the weeks during the follow-up, BP II patients being symptomatic 57 % of the weeks, and BP I patients symptomatic 47 % of total weeks. Secondly, the long-term symptomatic course of all three affective disorders is dominated by depressive symptoms. Thirdly, despite the fact that all three affective disorders have traditionally been defined by their syndromal episodes, the long-term symptomatic course of all three is dominated by more moderate and subsyndromal affective symptoms. Fourthly, the longitudinal symptomatic expression of all three mood disorders is dimensional in that affective symptom severity levels ranging from subsyndromal to syndromal levels fluctuate frequently within the same bipolar patient over time. These considerations add further evidence for the position of those who have argued for a broad affective disorder spectrum indicating a closer relationship between bipolarity and highly recurrent unipolarity (e.g. Akiskal, 1983; Cassano et al., 1989; Gershon et al., 1982; Goodwin and Jamison, 1990) . This proposal for a spectrum on the grounds of clinical psychopathological and course characteristics does not exclude the distinct possibility of underlying genetic variation (see e.g. Endicott et al., 1985; McMahon et al., 2001; MacKinnon et al., 2002; Rotondo et al., 2002) .
